-
As this industry continues to expand and reach new levels of acceptance and opportunities, the need for quality surgeons utilizing our programs grows with it.
-
The Centers for Medicare & Medicaid Services (CMS) offers a preview of a privacy authorization form that includes the core elements and necessary statements required in the privacy rule of the Health Insurance Portability and Accountability Act (HIPAA) of 1996.
-
Question: If an employee works out of his or her home, either full-time or part-time (e.g. during maternity leave, on weekends or evenings, or as part of telecommuting job description), do the HIPAA security regulations apply? If so, how do we ensure compliance?
-
The Department of Health and Human Services Office of Inspector General (OIG) has reported that the $150 Medicare payment for intraocular lenses (IOLs) is more than the cost of IOLs to surgery centers. OIG recommends that the Medicare payment be reduced in a manner that consider the different types and costs of IOLs.
-
Since 1996, the Food and Drug Administration (FDA) has received reports of more than 110 adverse events related to absorbable hemostatic agents, including 11 that resulted in paralysis or other neural deficits.
-
From an IRB members perspective, these are trying times. On the one hand, investigators complain that regulations for human subjects research and IRBs are too stringent, making it difficult for them to do their studies. Alternatively, human subjects advocates continually complain that IRBs and institutions are too lax in monitoring clinical studies.
-
A consortium of hospital systems in the Minneapolis-St. Paul area has implemented a program to standardize protocols for handwritten prescriptions. The effort integrates Joint Commission on Accreditation of Healthcare Organizations goals for 2004 targeting the elimination of dangerous abbreviations.
-
New research shows that mutations in the epidermal growth factor receptor (EGFR) gene correlate with clinical responsiveness in patients with non-small-cell lung cancer to the tyrosine kinase inhibitor gefitinib (Iressa).
-
Continued from the May 1, 2004 isssue. Part 2: Clinical Trials Summary, Recommendations, and Criteria for Use.
-
